Prostate

Open Clinical Trials

Nivolumab, Rucaparib, Docetaxel, Enzalutamide

Protocol Number: USOncology 17-149 (www.clinicaltrials.gov)
A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer – OPEN TO ENROLLMENT

Rucaparib

Protocol Number: USOncology 16237 (TRITON 2) (www.clinicaltrials.gov)
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency – OPEN TO ENROLLMENT

Rucaparib

Protocol Number: USOncology 16238 (TRITON 3) (www.clinicaltrials.gov)
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency